About Us

Immunovant, Inc.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401 (“batoclimab”), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Ronald Bates, PhD

Ronald Bates, PhD

Ronald Bates, Ph.D. is the Vice President of CMC Process Development and Technical Operations at Immunovant. Prior to joining Immunovant, Ron was a Director of Manufacturing Science and Technology (MSAT) at Bristol-Myers Squibb in Syracuse, NY where he was part of the development and commercialization of numerous protein therapeutics. Dr. Bates has more than 20 years of experience in the biopharmaceutical industry holding roles of increasing responsibility in Process Development and MSAT with Pfizer, Allergan, and Bristol-Myers Squibb. He is active in the scientific community with over 50 publications and presentations, chaired dozens of conference sessions and roundtable discussions, and he is a member of the Editorial Board of the Biotechnology Journal.

Dr. Bates earned a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and a Ph.D. in Biochemical Engineering from the University of Maryland, Baltimore County.

Andy Deig

Andy Deig

Andy Deig is Vice President of Financial Planning and Analysis and Chief of Staff to the CEO at Immunovant. Prior to joining Immunovant, Andy spent almost 13 years at Eli Lilly & Company where he held numerous roles in different functions across the business, including finance, sales, and value & access. Most recently, Andy served as the national account manager for McKesson and Walmart after leading the commercial integration of Dermira.

Andy earned a B.A. from Wabash College in 2008 with majors in Economics and German and an M.B.A. in health sector management and strategy from Duke’s Fuqua School of Business in 2016.

Thomas Hardy, MD, PhD

Thomas Hardy, MD, PhD

Thomas Hardy, MD, PhD is Vice President of Drug Safety and Pharmacovigilance at Immunovant.

Prior to joining Immunovant, Dr. Hardy spent 18 years at Eli Lilly and Company, holding key roles in all phases of Clinical Development. While in Early Phase Medicine at Lilly, Tom oversaw numerous IND filings and directed the design and implementation of over 30 phase 1 and 2 clinical trials of small and large molecule investigational agents across multiple disease areas. He subsequently directed the global registration trials and regulatory filings for late-phase assets in the Diabetes Business Unit, resulting in the global approvals of Baqsimi® and Lyumjev®. Before joining Lilly, he ran a busy clinical practice in Endocrinology.

He holds a B.A. in Biology from the University of California, Santa Cruz and an M.D. and Ph.D. (Biochemistry) from Indiana University. He completed fellowship training in Diabetes, Endocrinology and Metabolism at Vanderbilt University Medical Center.

Daniel Isaacman

Daniel Isaacman

Daniel Isaacman is Vice President of Clinical Development at Immunovant.

Dr. Isaacman attended medical school at the University of Pennsylvania School of Medicine, completed his pediatric residency at The Children’s Hospital of Philadelphia and his Pediatric Emergency Medicine fellowship at the Children’s Hospital of Pittsburgh.

Dan spent 17 years in Academic Medicine and served as Division Chief, Emergency Medicine at Children’s Hospital of The King’s Daughters before transitioning to industry at Wyeth. There, Dan spent 7 years working on the Prevnar/Prevnar 13 franchise and then transitioned to Clinical Development positions at pharmaceutical organizations including, Merck and Janssen. Dan has worked on the clinical development of a number of biologics and small molecules including FcRn inhibitors and has served as a Clinical Development consultant for a number of small and medium sized companies. Additionally, Dan has served as a Global Therapeutic Area Lead in Infectious Diseases and Pediatrics/Rare Disease at Parexel and IQVIA.

Chedvi Levin-Sister

Chedvi Levin-Sister

Chedvi Levin-Sister is Vice President of SEC Reporting, Technical Accounting and Tax at Immunovant. Prior to joining Immunovant, Chedvi spent over 15 years at PwC where she held numerous roles, most recently as Assurance Director, serving a range of industries and global clients including large pharmaceutical organizations, life science, medical device, SEC registrant, technology and start-up companies.

Chedvi’s expertise includes regulatory compliance of PCAOB, US GAAP, US GAAS, SEC and IFRS, technical and income tax accounting, revenue recognition (inclusive of Gross-to-net in domestic US Pharmaceutical companies), stock-based compensation and leases; she has deep transactional experience in carve-out and business combinations along with implementation of internal controls over financial reporting and remediation of material weaknesses.

Chedvi earned a B.A (cum laude) from The Jerusalem College of Technology (JCT), Israel, in 2005, in Management Accounting (Major) and Information System (Minor); she is a CPA (Isr.)

Jody Roth, MS, RAC, PMP

Jody Roth, MS, RAC, PMP

Jody Roth, RAC, PMP is the Vice President of Global Regulatory Affairs. Most of her career has been focused on autoimmune and oncology therapeutic areas.

Prior to joining Immunovant Ms. Roth held positions with biotech companies as Vice President of Regulatory and Quality as well as COO for several global oncology teams where her leadership resulted in registrations across multiple regions. Jody spent 25 years at Eli Lilly and Company in drug development from discovery to post-marketing phases and across multiple therapeutic areas. She has expertise in global development with emphasis on the US (FDA), EU (EMA), Canada (Health Canada), China and Japan (PMDA). She obtained US approvals for BLAs, and NDAs. She filed multiple INDs and regulatory documents for CTAs to support initiation of new molecules for clinical development.

She is recognized for her communication and advocacy of the label in mind concepts, as well as her expertise in FDA interactions.

Jody obtained her B.S. and M.S. from Purdue University. Her master’s degree was in growth physiology/immunology.

Rod Saponjic PhD, MBA

Rod Saponjic PhD, MBA

Dr. Saponjic is the Vice President Clinical Operations at Immunovant. Dr. Saponjic has more than 25 years of drug development experience in the areas of global operations, project management, clinical operations, clinical systems and CRO Management. Prior to Immunovant, he was the Vice President, Clinical Operations at Respivant responsible for development of RVT1601 for the treatment of Idiopathic Pulmonary Fibrosis patients, clinical department management, and member of Executive Leadership Team. Prior to Respivant, he was Vice President Global Development Operations at Greenwich Biosciences, responsible for development governance structures, clinical operations, portfolio pipeline process, and supporting the NDA submission and FDA approval for Epidiolex®. Prior to Greenwich, he held senior management positions at biotech, CRO, and Genomics companies including: AirPharma, Alkensa Clingenix, Monitorforhire.com, Patara Pharma, Quintiles, and Synteract. He earned a BA in Psychology at Texas Tech University, MS and PhD in Neuroscience at Texas Christian University, and an MBA from Baker University.

Lauren Schrier, MBA

Lauren Schrier, MBA

Lauren Schrier, M.B.A., is Vice President of Marketing at Immunovant. Prior to joining Immunovant, Lauren spent nearly 8 years at Celgene, where she held leadership roles including Project Leader of Otezla Dermatology and Chief of Staff of the Inflammation and Immunology franchise. While in Global Marketing and Commercial Development, Lauren was responsible for new product planning initiatives supporting the global commercialization of Otezla, franchise business development and portfolio strategies.

Prior to Celgene, Lauren worked in management consulting at Accenture and Easton Associates, where she advised biopharma and medtech companies in market assessment and strategy development engagements.

Lauren earned a B.S.E. in Chemical Engineering from the University of Pennsylvania, and an M.B.A. in Healthcare and Pharmaceutical Management from Columbia Business School.

Lesa Valentine

Lesa Valentine

Lesa Valentine is Vice President, Quality at Immunovant. Prior to joining Immunovant Lesa served as the Head of Global Quality at SanBio Inc, where she advanced the Quality Management System in support of a regenerative cell therapy product. Her background includes executive quality roles where she developed and implemented global systems and processes, assuring compliance and strategic risk mitigation across both development and commercial products for organizations such as Aimmune, Exelixis Genentech and Novartis.

Lesa earned a B.S. in Microbiology from University of Wyoming and is a member of The Parenteral Drug Association (PDA) and The Society of Quality Assurance (SQA).

Yan Zheng, PhD

Yan Zheng, PhD

Yan Zheng is the Vice President of Biostatistics and Programming at Immunovant. Yan has more than 15 years of drug development experience in industry holding various roles with Sarepta Therapeutics, Merck, Allergan, and Sanofi.

Prior to joining Immunovant Ms. Zheng served as the Head of Biometrics at Kaleido Biosciences, where she built and led the Biometrics team as well as the strategic and operational planning of biometrics resources and contributions. Yan possesses broad knowledge in diverse aspects of drug development including global program development planning, multi-regional clinical trial designing, conducting and analyzing across several therapeutical areas.

Yan earned a B.S. in Probability and Statistics from Peking University in China, and a M.S. and Ph.D. in Biostatistics from the University of Minnesota – Twin Cities, Minnesota.

Pete Salzmann, MD, MBA

Pete Salzmann, MD, MBA

Peter Salzmann, M.D., M.B.A. is the Chief Executive Officer of Immunovant and a member of Immunovant’s board of directors. From November 2018 to June 2019, he served as a Global Development Leader in Immunology at Eli Lilly and Company, where he was responsible for the design of a comprehensive indication strategy and Phase 2 and 3 clinical trial execution. From May 2013 to October 2018, Dr. Salzmann was Head of U.S. Immunology at Eli Lilly, and he also served as Managing Director of Lilly Alps from January 2011 to April 2013. From January 2008 to December 2010, Dr. Salzmann was the Head of Marketing for Eli Lilly China.

Dr. Salzmann earned a B.A. in Chemistry from Northwestern University, an M.D. from University of Chicago’s Pritzker School of Medicine, and an M.B.A. from Stanford University’s Graduate School of Business.

Renee Barnett, MBA

Renee Barnett, MBA

Renee Barnett, MBA is Chief Financial Officer of Immunovant.  With two decades of experience in healthcare, Ms. Barnett is a passionate and effective leader who thrives in fast-paced, growth organizations. Ms. Barnett began her career at Eli Lilly where her roles included CFO of Lilly Austria and Switzerland, global lead for Financial Planning and Analysis, and financial lead of a partnership with Amylin pharmaceuticals.  Prior to joining Immunovant, she served in a variety of executive leadership functions, including Finance, Human Resources, Data & Analytics, Call Center Operations, and Technology Transformation at AbleTo, Inc., a leading technology-enabled behavioral health provider.  Ms. Barnett holds an MBA from Harvard Business School, and a BA in Physics from DePauw University.

Julia G. Butchko, PhD

Julia G. Butchko, PhD

Julia G. Butchko, Ph.D. is the Chief Development and Technology Officer of Immunovant. Prior to joining Immunovant, Dr. Butchko oversaw strategy and operations as Chief of Staff for the $4 billion Immunology and Neuroscience businesses at Lilly. She previously served as Vice President of Lilly’s Oncology Project Management and Clinical Development teams where she was responsible for over 100 global clinical trials, including immuno-oncology collaborations with Merck, Bristol-Myers Squibb, and AstraZeneca. Earlier in her career, Dr. Butchko held significant roles in product development, marketing, manufacturing, and quality.

She holds a B.S. in Chemistry from the State University of New York at Fredonia, a Ph.D. in Chemistry from Pennsylvania State University and a Business Certificate from Indiana University Kelley School of Business.

Bill Macias, MD, PhD

Bill Macias, MD, PhD

William (Bill) Macias, MD, PhD is the Chief Medical Officer at Immunovant. From 2018 to May 2021, he was the Chief Executive Officer at Focus Biomedical Consulting LLC and in that role was the ad interim Chief Medical Officer for Promethera Biosciences SA from 2019 through 2020. From 1994 through 2017, Dr. Macias was at Eli Lilly and Company. At Lilly he led multiple clinical development programs leading to the submission and approval of medications across diverse therapeutic areas in both biologic and small molecules. From 2011 onward, he held multiple global development leadership roles in the Biomedicines Business Unit. Prior to joining Eli Lilly and Company, he was an Associate Professor of Medicine at Indiana University School of Medicine.

Dr. Macias earned a B.A. in Biology from Marquette University and both an M.D. and Ph.D. from Indiana University School of Medicine. He held board certifications in Internal Medicine, Nephrology, and Critical Care Medicine.

Our Board of Directors

Frank Torti, M.D. is Executive Chairperson of Immunovant’s board of directors. Since January 2020, Dr. Torti served as the Vant Chair of Roivant Sciences, Inc. (RSI), where he previously worked as Vant Investment Chair. Prior to joining RSI, Dr. Torti served as a Partner of New Enterprise Associates (NEA), specializing in investments in healthcare. Before NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti presently serves as Chairperson of the board of directors of Arbutus Biopharma Corp., Axovant Gene Therapies Ltd. and several private biopharmaceutical companies. Dr. Torti earned an M.D. from the University of North Carolina School of Medicine, an M.B.A. from Harvard Business School and a B.A. from the University of North Carolina.

Andrew Fromkin is the Vant Portfolio Operating Partner for Roivant Sciences, serves as the Acting CEO of PharmaVant 5 (focused on Protein Degradation) and serves on the board of Immunovant (NASDAQ: IMVT) as chair of the compensation and nominating and governance committees. Mr. Fromkin most recently served as Chief Executive Officer of Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.). From 2005 until 2011, Mr. Fromkin served in various roles for Clinical Data, Inc., including Executive Vice President (October 2005 until May 2006), President, Chief Executive Officer and Director (May 2006 until May 2011). Prior to Clinical Data, Mr. Fromkin served as President and Chief Executive Officer of DoctorQuality, Inc., President, Chief Executive Officer and Director of Endo Surgical Devices, Inc. and Corporate Vice President, Business Development, for Merck-Medco, a wholly-owned subsidiary of Merck & Co. Mr. Fromkin began his career at Health Information Technologies, Inc. as General Manager of its subsidiary, MCA, and Director of Marketing and Payer Alliances for the parent company. From 2014 until 2016, Mr. Fromkin served on the board of Regado Biosciences, Inc. which became Tobira Therapeutics, Inc. in 2015. Mr. Fromkin received a B.A. from Brandeis University.

Douglas Hughes is a member of Immunovant’s board of directors. Since 2018, Mr. Hughes has served as Chief Financial Officer of Kalera Medical, an early stage medical device company. From 2011 until 2018, Mr. Hughes was Chief Financial Officer for NeoTract, Inc., a Urology company. Prior to that time, he served as Chief Financial Officer and Chief Operating Officer for Nellix, Inc., an endovascular graft biotechnology company. Before joining Nellix, Inc., Mr. Hughes served as Chief Financial officer for Evalve Inc., a medical device company, from 2009 until 2010. Prior to 2010, Mr. Hughes held a variety of senior finance management positions at Boston Scientific, Guidant Corporation and The Clorox Company. Mr. Hughes is currently a director at Kalera Medical, Inc., a position held since 2018. Mr. Hughes received a B.S. in Finance from San Francisco State University and an M.B.A. from University of Chicago.

George Migausky is a member of Immunovant’s board of directors. In 2017, Mr. Migausky served as interim Chief Financial Officer for Ocular Therapeutix, Inc. Prior to that, he served as Executive Vice President and Chief Financial Officer of Dyax Corp. a position he held from 2008 through the company’s acquisition by Shire for $6.4 billion in 2016. Before joining Dyax, Mr. Migausky served as Chief Financial Officer of Wellstat Management Company from 2007 to 2008; and Chief Financial Officer of IGEN International and BioVeris Corporation from 1986 through their acquisitions by F. Hoffman LaRoche in 2004 and 2007, respectively. Current directorships include Hyperion Catalysis International, a position he has held since 2008, and the Massachusetts Eye and Ear Institute, where he has served as a trustee since 2015. Mr. Migausky has previously served on the board of directors as Chair of the audit committee at Dimension Therapeutics, a position he held from 2015 until the company was acquired in 2017. Mr. Migausky received his BS from Boston College and his MBA from Babson College.

Atul Pande, M.D. is a member of Immunovant’s board of directors. Dr. Pande has extensive experience in treatment development across multiple disease areas. He is currently an independent board member of Axovant Gene Therapies, Karuna Therapeutics, Autifony Therapeutics, and Perception Neurosciences. He previously served as the Chief Medical Officer of PureTech Health, Chief Medical Officer of Tal Medical, and medical advisor to PureTech Health. Since April 2014, he has also served as President of Verity BioConsulting, a drug development consulting firm that provides services to clients in the biopharmaceutical business. From 2007 to April 2014, Dr. Pande was Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline. He has also held senior roles at Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. He has been on the Scientific Advisory Boards of Cennerv Pharma and Centrexion Corporation. Dr. Pande is a physician who completed his research fellowship training in psychiatry at the University of Michigan Medical School and his postgraduate specialty training and psychiatry residency program at Western University.

Peter Salzmann, M.D., M.B.A. is the Chief Executive Officer of Immunovant and a member of Immunovant’s board of directors. From November 2018 to June 2019, he served as a Global Development Leader in Immunology at Eli Lilly and Company, where he was responsible for the design of a comprehensive indication strategy and Phase 2 and 3 clinical trial execution. From May 2013 to October 2018, Dr. Salzmann was Head of U.S. Immunology at Eli Lilly, and he also served as Managing Director of Lilly Alps from January 2011 to April 2013. From January 2008 to December 2010, Dr. Salzmann was the Head of Marketing for Eli Lilly China.

Dr. Salzmann earned a B.A. in Chemistry from Northwestern University, an M.D. from University of Chicago’s Pritzker School of Medicine, and an M.B.A. from Stanford University’s Graduate School of Business.

Eric Venker, M.D., Pharm.D. is a member of Immunovant’s board of directors. Since February 2021, Dr. Venker has served as President, Chief Operating Officer of Roivant Sciences, Inc. (RSI), having previously served as Chief Operating Officer of RSI since November 2018. Previously, he was Chief of Staff to RSI’s Chief Executive Officer. From 2015 to 2017, Dr. Venker was a physician at New York Presbyterian Hospital/Columbia University Medical Center, where he trained in internal medicine, and also served as Chair of the Housestaff Quality Council leading operational initiatives to improve efficiencies. Dr. Venker also worked as a Clinical Pharmacist at Yale-New Haven Hospital. Dr. Venker presently serves on the boards of directors of Arbutus Biopharma Corp., Sio Gene Therapies, Inc. and several private biopharmaceutical companies. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine.